Table 1 Select baseline demographics and disease characteristics.
ARIEL2 Part 1 (n = 204) | ARIEL2 Part 2 (n = 287) | |
|---|---|---|
Age, median (range), years | 64.5 (31.0–86.0) | 63.0 (35.0–91.0) |
ECOG PS, n (%) | ||
0 | 134 (65.7) | 134 (46.7) |
1 | 70 (34.3) | 151 (52.6) |
≥2 | 0 | 2 (0.7) |
Cancer type, n (%) | ||
Epithelial ovarian cancer | 164 (80.4) | 234 (81.5) |
Primary peritoneal cancer | 24 (11.8) | 28 (9.8) |
Fallopian tube cancer | 16 (7.8) | 25 (8.7) |
Histology, n (%)a | ||
Serous | 197 (96.6) | 269 (93.7) |
Endometrioid | 4 (2.0) | 12 (4.2) |
Mixed | 3 (1.5) | 6 (2.1) |
No. of prior chemotherapy regimens, median (range) | 1 (1–6) | 3 (2–5) |
No. of prior chemotherapy regimens, n (%) | ||
1 | 119 (58.3) | 0 |
2 | 52 (25.5) | 2 (0.7)b |
3 | 24 (11.8) | 186 (64.8) |
4 | 5 (2.5) | 97 (33.8) |
≥5 | 4 (2.0) | 2 (0.7) |
No. of platinum-based regimen, median (range) | 1 (1–5) | 3 (1–4) |
Platinum status, n (%) | ||
Sensitive | 202 (99.0) | 81 (28.2) |
Resistant | 2 (1.0) | 158 (55.1) |
Refractory | 0 | 48 (16.7) |
No. of non-platinum regimens following last platinum regimen, n (%) | ||
0 | 204 (100.0) | 81 (28.2) |
1 | 0 | 150 (52.3) |
2 | 0 | 52 (18.1) |
3 | 0 | 4 (1.4) |
